Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21‐1 and TPS in oral squamous cell carcinoma

Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma

“…Many serum tumour markers have been examined to detect OSCC 12,15,18 , but unfortunately, up to now no specific tumour marker has been found.…”

Tissue and serum borne tumor markers of oral squamous cell carcinoma: present and forthcoming therapeutic roles

“…In any case the main drawback of most of these markers was their relatively low sensitivity for head and neck carcinoma. However, recent data point to the suitability of the clinical use of two serum borne markers, TPS and particularly Cyfra 21-1 in the early detection of oral SCC lesions (primary, recurrent, or secondary) as well as for treatment monitoring [55]. Both markers are soluble forms of keratins in human sera that are relatively new in the field of monitoring cancer patients.…”

“…Thus both markers were shown to have a dual role in diagnosis and treatment monitoring. These results may open new avenues for the diagnosis and follow-up of these patients and hopefully improve their treatment outcome [55].…”

“…The overall 5-year survival rate for patients with head and neck squamous cell carcinoma (SCC) is among the lowest for major cancers and has not changed during the past two decades [2,7,23,39,43,47,55,56,58,66,67,73,89]. Despite therapeutic and diagnostic progress in oncology during the past decades the prognosis of intraoral SCC remains poor; however, very recent statistics indicate a decrease in the number of deaths associated with oral carcinoma [74].…”

Simultaneous quantitative detection of multiple tumor markers with a rapid and sensitive multicolor quantum dots based immunochromatographic test strip

“…Detecting multiple tumor markers s at early age facilitates diagnosis of cancer and treatment monitoring (Nagler et al, 1999;Duffy et al, 2003), and significantly improves the treatment efficiency and survival rates ( McMahon et al, 2000;Pantel et al, 2008). However, detecting only a single tumor maker is usually inadequate for an accurate diagnosis of cancer since most are not specific to a particular tumor.…”